Literature DB >> 11702861

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome.

G E Keles1, K R Lamborn, M S Berger.   

Abstract

OBJECT: The goal of this study was to perform a critical review of literature pertinent to low-grade gliomas of the cerebral hemisphere in adults and, on the basis of this review, to evaluate systematically the prognostic effect of extent of resection on survival and to determine if treatment-related guidelines could be established for patients in whom these tumors have been newly diagnosed. Quality of evidence for current treatment options, guidelines, and standards as well as methodological limitations were evaluated.
METHODS: Several prognostic factors thought to affect outcome in patients with low-grade gliomas include the patient's age and neurological status, tumor volume and histological characteristics, and treatment-related variables such as timing of surgical intervention, extent of resection, postoperative tumor volume, and radiation therapy. Patient age and the histological characteristics of the lesion are generally accepted prognostic factors. Among treatment-related factors, timing and extent of resection are controversial because of the lack of randomized controlled trials addressing these issues and the difficulty in obtaining information from available studies that have methodological limitations. All English-language studies on low-grade gliomas published between January 1970 and April 2000 were reviewed. Thirty studies that included statistical analyses were further evaluated with regard to the prognostic effect of extent of resection. Of these 30 studies, those that included pediatric patients, unless adults were analyzed separately, were excluded from further study because of the favorable outcome associated with the pediatric age group. Also excluded were studies including pilocytic and gemistocytic astrocytomas, because the natural histories of these histological subtypes are significantly different from that of low-grade gliomas. Series in which there were small numbers of patients (< 75) were also excluded. Results for oligodendrogliomas are reported separately. Currently, for patients with low-grade glial tumors located in the cerebral hemisphere, the only management standard based on high-quality evidence is tissue diagnosis. All other treatment methods are practice options supported by evidence that is inconclusive or conflicting. The majority of published series that the authors identified had design-related limitations including a small study size, a small number of events (that is, deaths for survival studies), inclusion of pediatric patients, and/or inclusion of various histological types of tumors with different natural histories. Of the 30 series addressing the issue of timing and extent of surgery, almost all had additional design limitations. Methods used to determine the extent of resection were subjective and qualitative in almost all studies. Only five of the 30 series met the authors' criteria, and these studies are discussed in detail.
CONCLUSIONS: Management of low-grade gliomas is controversial and practice parameters are ill defined. This is caused by limited knowledge regarding the natural history of these tumors and the lack of high-quality evidence supporting various treatment options. Although a prospective randomized study seems unlikely, both retrospective matched studies and prospective observational trials will improve the clinician's ability to understand the importance of various prognostic factors.

Entities:  

Mesh:

Year:  2001        PMID: 11702861     DOI: 10.3171/jns.2001.95.5.0735

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  97 in total

1.  Improving the time-machine: estimating date of birth of grade II gliomas.

Authors:  C Gerin; J Pallud; B Grammaticos; E Mandonnet; C Deroulers; P Varlet; L Capelle; L Taillandier; L Bauchet; H Duffau; M Badoual
Journal:  Cell Prolif       Date:  2011-12-14       Impact factor: 6.831

2.  Evaluating requirements for spatial resolution of fMRI for neurosurgical planning.

Authors:  Seung-Schik Yoo; Ion-Florin Talos; Alexandra J Golby; Peter McL Black; Lawrence P Panych
Journal:  Hum Brain Mapp       Date:  2004-01       Impact factor: 5.038

3.  Functional recovery after surgical resection of low grade gliomas in eloquent brain: hypothesis of brain compensation.

Authors:  H Duffau; L Capelle; D Denvil; N Sichez; P Gatignol; M Lopes; M-C Mitchell; J-P Sichez; R Van Effenterre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

4.  The dilemma of low grade glioma.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

5.  Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps.

Authors:  Antonella Castellano; Marina Donativi; Roberta Rudà; Giorgio De Nunzio; Marco Riva; Antonella Iadanza; Luca Bertero; Matteo Rucco; Lorenzo Bello; Riccardo Soffietti; Andrea Falini
Journal:  Eur Radiol       Date:  2015-08-30       Impact factor: 5.315

6.  Gross total resection of low-grade glioma in adults.

Authors:  Lauren E Abrey
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

7.  Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.

Authors:  Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2020-01-24       Impact factor: 4.130

8.  Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Authors:  A Smits; E Westerberg; D Ribom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

Review 9.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

10.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.